Back

Changing focus in diabetes: From glucose to cardiovascular risk management.

27 August 2018 (13:05 - 13:35)
Organised by:
Congress Presentation Part of: Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited) Diabetes and the Heart ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Stephan Jacob

Villingen (Germany)

4 More presentations in this session

Presentation thumbnail
Introduction - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.
Professor F. Cosentino (Stockholm, SE)
Presentation thumbnail
SGLT2 inhibition in cardiology: what is the profile of benefit? .
Professor N. Marx (Aachen, DE)
Presentation thumbnail
Heart failure & SGLT2: with or without diabetes?
Professor J. McMurray (Glasgow, GB)
Presentation thumbnail
Discussion - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.
Professor F. Cosentino (Stockholm, SE)

Access the full session

Session thumbnail
Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)

The Event

Event poster

ESC Congress 2018

27 August 2018 13:05 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources